JP2008533191A5 - - Google Patents

Download PDF

Info

Publication number
JP2008533191A5
JP2008533191A5 JP2008502453A JP2008502453A JP2008533191A5 JP 2008533191 A5 JP2008533191 A5 JP 2008533191A5 JP 2008502453 A JP2008502453 A JP 2008502453A JP 2008502453 A JP2008502453 A JP 2008502453A JP 2008533191 A5 JP2008533191 A5 JP 2008533191A5
Authority
JP
Japan
Prior art keywords
compound
compound according
alkyl
alaninyl
phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008502453A
Other languages
English (en)
Japanese (ja)
Other versions
JP5345381B2 (ja
JP2008533191A (ja
Filing date
Publication date
Priority claimed from GBGB0505781.5A external-priority patent/GB0505781D0/en
Application filed filed Critical
Publication of JP2008533191A publication Critical patent/JP2008533191A/ja
Publication of JP2008533191A5 publication Critical patent/JP2008533191A5/ja
Application granted granted Critical
Publication of JP5345381B2 publication Critical patent/JP5345381B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008502453A 2005-03-21 2006-03-16 癌の治療における使用のためのヌクレオシド化合物のホスホルアミデート誘導体 Expired - Fee Related JP5345381B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0505781.5A GB0505781D0 (en) 2005-03-21 2005-03-21 Chemical compounds
GB0505781.5 2005-03-21
PCT/GB2006/000932 WO2006100439A1 (en) 2005-03-21 2006-03-16 Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013097919A Division JP5863702B2 (ja) 2005-03-21 2013-05-07 癌の治療における使用のためのヌクレオシド化合物のホスホルアミデート誘導体

Publications (3)

Publication Number Publication Date
JP2008533191A JP2008533191A (ja) 2008-08-21
JP2008533191A5 true JP2008533191A5 (US20080242721A1-20081002-C00053.png) 2009-04-30
JP5345381B2 JP5345381B2 (ja) 2013-11-20

Family

ID=34531603

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008502453A Expired - Fee Related JP5345381B2 (ja) 2005-03-21 2006-03-16 癌の治療における使用のためのヌクレオシド化合物のホスホルアミデート誘導体
JP2013097919A Active JP5863702B2 (ja) 2005-03-21 2013-05-07 癌の治療における使用のためのヌクレオシド化合物のホスホルアミデート誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013097919A Active JP5863702B2 (ja) 2005-03-21 2013-05-07 癌の治療における使用のためのヌクレオシド化合物のホスホルアミデート誘導体

Country Status (20)

Country Link
US (1) US8263575B2 (US20080242721A1-20081002-C00053.png)
EP (1) EP1866324B1 (US20080242721A1-20081002-C00053.png)
JP (2) JP5345381B2 (US20080242721A1-20081002-C00053.png)
CN (2) CN101175763A (US20080242721A1-20081002-C00053.png)
AT (1) ATE471334T1 (US20080242721A1-20081002-C00053.png)
AU (1) AU2006226182C1 (US20080242721A1-20081002-C00053.png)
BR (1) BRPI0609704B8 (US20080242721A1-20081002-C00053.png)
CA (1) CA2602324C (US20080242721A1-20081002-C00053.png)
CY (1) CY1111538T1 (US20080242721A1-20081002-C00053.png)
DE (1) DE602006014949D1 (US20080242721A1-20081002-C00053.png)
DK (1) DK1866324T3 (US20080242721A1-20081002-C00053.png)
ES (1) ES2348741T3 (US20080242721A1-20081002-C00053.png)
GB (1) GB0505781D0 (US20080242721A1-20081002-C00053.png)
IL (1) IL186104A (US20080242721A1-20081002-C00053.png)
MX (1) MX2007011666A (US20080242721A1-20081002-C00053.png)
PL (1) PL1866324T3 (US20080242721A1-20081002-C00053.png)
PT (1) PT1866324E (US20080242721A1-20081002-C00053.png)
SI (1) SI1866324T1 (US20080242721A1-20081002-C00053.png)
WO (1) WO2006100439A1 (US20080242721A1-20081002-C00053.png)
ZA (1) ZA200709011B (US20080242721A1-20081002-C00053.png)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
AU2012216500B2 (en) * 2006-11-24 2013-06-20 Katholieke Universiteit Leuven Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
BRPI1004575A2 (pt) 2009-01-09 2016-04-05 Inhibitex Inc composto, composição farmacêutica, método de tratamento de infecções virais, método de separação dos diaestereômeros de fósforo
JP2013527145A (ja) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
GB201016855D0 (en) * 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
EP2658857B1 (en) 2010-12-29 2016-11-02 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
CN103403014B (zh) * 2011-01-03 2016-07-06 河南美泰宝生物制药有限公司 O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途
DK3031812T3 (en) * 2011-03-01 2018-09-17 NuCana plc CHEMICAL COMPOUNDS
WO2012125900A1 (en) 2011-03-16 2012-09-20 Enanta Pharmaceuticals, Inc. 2'-allene-substituted nucleoside derivatives
NZ708177A (en) 2012-11-16 2017-08-25 Univ College Cardiff Consultants Ltd Process for preparing nucleoside prodrugs
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
AU2014354775A1 (en) * 2013-11-27 2016-05-19 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
RU2016149761A (ru) * 2014-05-28 2018-07-02 АЙДЕНИКС ФАРМАСЬЮТИКАЛЗ ЭлЭлСи Производные нуклеозидов для лечения ракового заболевания
CA2947939A1 (en) * 2014-05-28 2015-12-03 Idenix Pharmaceuticals Llc Nucleoside derivatives for the treatment of cancer
IL291927A (en) 2014-11-28 2022-06-01 NuCana plc Oligonucleotides containing modified nucleosides
IL295418B2 (en) 2015-03-06 2023-10-01 Atea Pharmaceuticals Inc Cell-D-2'-deoxy-2'-alpha-fluoro-2'-cell-C-modified-2-different-N6-purine modified nucleotides for the treatment of hepatitis C virus
MX2018005872A (es) 2015-11-16 2019-05-16 Ichorion Therapeutics Inc Profarmacos de acido nucleico.
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609602D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
GB201609601D0 (en) * 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
PT3512863T (pt) 2016-09-07 2022-03-09 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna
WO2018071675A1 (en) * 2016-10-12 2018-04-19 Georgetown University Cd99 inhibitors and their uses
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
CN113549076B (zh) * 2021-07-23 2022-12-06 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880000094B1 (ko) 1984-12-07 1988-02-23 보령제약 주식회사 뉴클레오시드 유도체의 제조방법
CA2004695C (en) 1988-12-12 1999-08-10 Rosanne Bonjouklian Phospholipid nucleosides
DE4418690A1 (de) * 1994-05-28 1996-01-11 Boehringer Mannheim Gmbh Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
JP4313847B2 (ja) 1995-04-21 2009-08-12 ユニヴァーシティ オブ サウス フロリダ 免疫賦活性イノシン一リン酸の5’−ヌクレオチダーゼ抵抗性誘導体およびその使用
JP3761958B2 (ja) 1996-03-12 2006-03-29 彰 松田 3′−カルバモイルアルキルヌクレオシド誘導体
ES2172303T3 (es) * 1998-01-23 2002-09-16 Newbiotics Inc Agentes terapeuticos obtenidos por catalisis enzimatica.
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
JP4768909B2 (ja) 2000-09-29 2011-09-07 扶桑薬品工業株式会社 トポイソメラーゼ阻害剤
US20030073618A1 (en) 2001-02-08 2003-04-17 Kozhemyakin Leonid A. Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof
DE10108851A1 (de) * 2001-02-23 2002-09-12 Resprotect Gmbh Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten
EP1478322A4 (en) 2001-06-22 2007-08-08 Pharmasset Ltd Beta 2'-OR 3'-HALONUCLEOSIDE
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
CA2571079A1 (en) * 2004-06-24 2006-02-02 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
CN101287472B (zh) * 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物

Similar Documents

Publication Publication Date Title
JP2008533191A5 (US20080242721A1-20081002-C00053.png)
JP2008505157A5 (US20080242721A1-20081002-C00053.png)
JP2019512478A5 (US20080242721A1-20081002-C00053.png)
JP2013537203A5 (US20080242721A1-20081002-C00053.png)
JP2005523922A5 (US20080242721A1-20081002-C00053.png)
JP2010530881A5 (US20080242721A1-20081002-C00053.png)
JP2008528447A5 (US20080242721A1-20081002-C00053.png)
JP2007511504A5 (US20080242721A1-20081002-C00053.png)
CA2565660A1 (en) Ortho substituted aryl or heteroaryl amide compounds
JP2008510828A5 (US20080242721A1-20081002-C00053.png)
JP2009535307A5 (US20080242721A1-20081002-C00053.png)
JP2009520695A5 (US20080242721A1-20081002-C00053.png)
JP2009502743A5 (US20080242721A1-20081002-C00053.png)
JP2009504763A5 (US20080242721A1-20081002-C00053.png)
JP2008510770A5 (US20080242721A1-20081002-C00053.png)
JP2011509309A5 (US20080242721A1-20081002-C00053.png)
JP2014503574A5 (US20080242721A1-20081002-C00053.png)
JP2006514012A5 (US20080242721A1-20081002-C00053.png)
JP2002516817A5 (US20080242721A1-20081002-C00053.png)
JP2009500423A5 (US20080242721A1-20081002-C00053.png)
JP2007501809A5 (US20080242721A1-20081002-C00053.png)
JP2008508287A5 (US20080242721A1-20081002-C00053.png)
EA200800502A1 (ru) Соединения 3-аминокарбазола, фармацевтическая композиция, содержащая указанные соединения, и способ их получения
MY145838A (en) Powder formulations for inhalation, comprising enantiomerically pure beta agonists
JP2003306481A5 (US20080242721A1-20081002-C00053.png)